Healthcare Industry News: chimeric antigen receptor
News Release - June 19, 2019
CARsgen Therapeutics Receives IND Clearance for BCMA-CAR-T Cells from the U.S. FDASHANGHAI, June 19, 2019 -- (Healthcare Sales & Marketing Network) -- CARsgen Therapeutics, a clinical-stage company committed to developing chimeric antigen receptor T cell therapies for cancer, today announced that one of its leading drug candidates, CT053 fully human BCMA (B-Cell Maturation Antigen)-CAR-T cell for the treatment of patients suffering from relapsed/refractory multiple myeloma (rrMM), has received Investigational New Drug (IND) clearance from the United States Food and Drug Administration (FDA). CT053 has also received IND clearance from the National Medical Products Administration in China four months ago and is the subject of an ongoing phase I clinical trial.
 JAMA Oncol. 2018;4(9):1221-1227. doi: 10.1001/jamaoncol.2018.2128. About CARsgen Therapeutics
CARsgen Therapeutics is a clinical-stage immune-oncology company committed to the development and commercialization of CAR-T therapeutics for unmet medical need. The company has collaborated with top hospitals in China to launch several First-in-Human studies such as CAR-GPC3-T for hepatocellular carcinoma and squamous lung cancer, CAR-EGFR/EGFRvIII-T for glioblastoma multiforme and CAR-Claudin18.2-T for gastric and pancreatic cancer.
For more information, please visit: www.carsgen.com
Source: CARsgen Therapeutics
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.